Chris Froome is reportedly ready to accept that he took an excess dose of salbutamol in the hope of receiving a six to nine-month ban so that he can return to racing in time for the Giro d’Italia or Tour de France.
The Team Sky rider, who returned an adverse analytical finding for the asthma drug at last year’s Vuelta a España, is currently training intensely in South Africa, having clocked up 4,500km since Christmas.
La Gazzetta dello Sport has claimed that Froome, who has not been provisionally suspended, will race for the first time at the Ruta del Sol in Spain from February 14-19. However, the Corriere della Sera newspaper reports that Froome "has understood he has lost the war and is ready to sign an honourable armistice".
ADVERTISEMENT
The Italian newspaper claims that Froome has little chance of convincing the UCI Legal Anti-Doping Services (LADS) that he reached a level of 2000ng/ml of salbutamol in his urine – twice the limit – through permitted dosages using his asthma inhaler.
Corriere della Sera also suggests the idea that Froome’s kidneys could have somehow retained a quantity of salbutamol and skewed his sample has only irritated the UCI and a number of cycling doctors, while the idea of undergoing a pharmacokinetic test in a laboratory could massively backfire. If Froome failed to reach a level close to that of the Vuelta a España, he would face a ban of between 12 and 24 months.
The newspaper claims that this lack of options has lead to Froome’s wife, Michelle, advising him to consider plea-bargaining with the UCI via an ‘Acceptance of Consequences’.
- Chris Froome returns adverse analytical finding for salbutamol
- Chris Froome: I haven't broken any rules
- Giro d'Italia director calls on UCI to 'sort out' Chris Froome's salbutamol case
- A lot of explaining to do: The questions raised by the Chris Froome salbutamol case
You can read more at Cyclingnews.com
via Cyclingnews Latest News http://www.cyclingnews.com/news/chris-froome-could-accept-salbutamol-responsibility-in-hope-of-lenient-ban
No comments:
Post a Comment